15.02
Precedente Chiudi:
$14.95
Aprire:
$14.885
Volume 24 ore:
50,567
Relative Volume:
0.60
Capitalizzazione di mercato:
$199.85M
Reddito:
$116.26M
Utile/perdita netta:
$-11.08M
Rapporto P/E:
-18.97
EPS:
-0.7917
Flusso di cassa netto:
$1.04M
1 W Prestazione:
-0.27%
1M Prestazione:
-0.53%
6M Prestazione:
+64.15%
1 anno Prestazione:
+30.61%
Anika Therapeutics Inc Stock (ANIK) Company Profile
Nome
Anika Therapeutics Inc
Settore
Telefono
(781) 457-9000
Indirizzo
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
ANIK
Anika Therapeutics Inc
|
15.02 | 198.92M | 116.26M | -11.08M | 1.04M | -0.7917 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-17 | Iniziato | B. Riley Securities | Buy |
| 2024-11-01 | Reiterato | Barrington Research | Outperform |
| 2023-08-14 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2023-03-07 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2022-11-09 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2022-10-14 | Ripresa | Stephens | Equal-Weight |
| 2022-03-09 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2022-03-09 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2021-11-16 | Iniziato | Stephens | Overweight |
| 2021-07-16 | Iniziato | UBS | Neutral |
| 2020-12-16 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2020-05-08 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-01-21 | Aggiornamento | Sidoti | Neutral → Buy |
| 2020-01-10 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2019-11-05 | Iniziato | BWS Financial | Sell |
| 2019-09-24 | Reiterato | Barrington Research | Outperform |
| 2019-09-23 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| 2019-07-25 | Aggiornamento | First Analysis Sec | Neutral → Strong Buy |
| 2019-02-22 | Downgrade | First Analysis Sec | Outperform → Neutral |
| 2019-02-22 | Downgrade | Sidoti | Buy → Neutral |
| 2018-07-27 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2018-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2018-06-20 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2018-05-04 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2018-02-23 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2018-01-24 | Aggiornamento | First Analysis Sec | Equal-Weight → Overweight |
| 2017-10-27 | Reiterato | Barrington Research | Outperform |
| 2016-05-09 | Aggiornamento | Singular Research | BUY - Long-Term → Buy |
| 2016-04-27 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2016-02-26 | Reiterato | Barrington Research | Outperform |
Mostra tutto
Anika Therapeutics Inc Borsa (ANIK) Ultime notizie
Anika Therapeutics Inc (ANIK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Anika Therapeutics Inc (ANIK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Anika Therapeutics Inc (ANIK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Anika Therapeutics Inc (ANIK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Anika Therapeutics Inc (ANIK) Cash Flow - TradingKey
Anika Therapeutics, Inc. Revenue Breakdown – BX:AKP - TradingView
Anika Therapeutics Inc (ANIK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Anika Therapeutics (ANIK) 2026 CG Musculoskeletal Conference Summary - Quartr
Anika Therapeutics (ANIK) Proxy filing Summary - Quartr
Anika Therapeutics (ANIK) Q4 2025 earnings summary - Quartr
Anika Therapeutics (ANIK) AGM 2026 Summary - Quartr
BlackRock Portfolio Management (NASDAQ: ANIK) discloses 4.1% Anika Therapeutics ownership - Stock Titan
Discipline and Rules-Based Execution in ANIK Response - Stock Traders Daily
Anika Therapeutics Expands Revolving Credit Facility Agreement - The Globe and Mail
Anika Therapeutics to issue Q2FY26 results on July 29 - scanx.trade
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026 - GlobeNewswire
Anika Therapeutics Enters Fifth Amendment To Credit AgreementSEC Filing - TradingView
Anika Therapeutics Extends $50M Revolver to 2031 With Bank of America; Upsize Option to $100M - TradingView
Anika Therapeutics (NASDAQ: ANIK) updates $50M revolving credit line terms - Stock Titan
Anika Therapeutics, Inc. Amends and Extends $50 Million Senior Revolving Credit Facility with Bank Of America, N.A - marketscreener.com
Price to book forward of Anika Therapeutics Inc. – NASDAQ:ANIK - TradingView
Price to earnings forward of Anika Therapeutics Inc. – NASDAQ:ANIK - TradingView
Anika Therapeutics Edges Higher Amid Consolidation: ANIK Stock Tests Key ResistanceALMA Signal - dars.gov.et
Anika Therapeutics extends implant lifespan with engineered Hyaff for regenerative medicine - Traders Union
Anika Therapeutics, Inc.(NasdaqGS:ANIK) dropped from Russell 2000 Value-Defensive Index - marketscreener.com
Anika Therapeutics, Inc.(NasdaqGS: ANIK) dropped from Russell 2000 Defensive Index - marketscreener.com
Early MRI scans uncover hidden risks in rotator cuff repair, Integrity Implant System data show - Traders Union
Anika Therapeutics, Inc. Actuals & Estimates (NASDAQ:ANIK) - TradingView
ANIK Forecast — Price Target — Prediction for 2027 - TradingView
Anika Therapeutics unveils Hyalofast cartilage repair scaffold using Hyaff hyaluronic acid technology - Traders Union
Behavioral Patterns of ANIK and Institutional Flows - Stock Traders Daily
Anika Shareholders Approve Directors and Expanded Incentive Plans - TipRanks
Director at Anika Therapeutics (NASDAQ: ANIK) receives 10,402 RSU grant - Stock Titan
Director at Anika Therapeutics (ANIK) receives 10,402 RSU award, holding 58,273 shares - Stock Titan
Anika Therapeutics (ANIK) director awarded 10,402 RSUs in stock grant - Stock Titan
[Form 4] Anika Therapeutics, Inc. Insider Trading Activity - Stock Titan
Director at Anika Therapeutics (ANIK) receives 10,402 RSUs equity grant - Stock Titan
Anika Therapeutics increases equity plan shares under amended omnibus and ESPP - TradingView
Anika Therapeutics (NASDAQ: ANIK) shareholders back equity plans and director slate - Stock Titan
Anika Therapeutics Inc (ANIK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Anika Therapeutics (ANIK) Q1 2026 Earnings: Massive EPS Surprise Driven by Operational EfficiencyGuidance vs Actual - dars.gov.et
Biologics may shift outcomes in tendon injuries, Anika Therapeutics explores - Traders Union
Anika Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Anika Therapeutics Inc (ANIK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Anika Therapeutics Inc (ANIK) Valuation: PE, PB & Fair Value Analysis - TradingKey
Anika Therapeutics Inc (ANIK) Institutional Confidence - TradingKey
Anika Therapeutics introduces Cingal as only approved HA and corticosteroid combination for OA pain - Traders Union
(ANIK) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Anika Therapeutics (ANIK) Holds Steady Near Support Amid Low VolumeMonthly Profile - newsline.com
Anika Therapeutics Q1 2026 Earnings: Massive EPS Beat Fuels OptimismConsensus Forecast Report - newsline.com
Anika Therapeutics (ANIK) Edges Higher as Shares Test Key Resistance LevelsInside Day Breakout - newsline.com
Anika Therapeutics Inc Azioni (ANIK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Anika Therapeutics Inc Azioni (ANIK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Griffin Stephen D. | President and CEO |
Apr 30 '26 |
Buy |
12.29 |
12,200 |
149,881 |
36,163 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):